TrialSignal transduction and targeted therapy2026

Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study.

Wenwei Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.